Starpharma Holdings Ltd has released a press release.
Starpharma commences phase 1/2 DEP irinotecan trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel BV launched in Europe
- Starpharma signs second oncology agreement with AstraZeneca
- DEP irinotecan combination outperforms in colon cancel model
- First VivaGel BV launch globally in Australia by Aspen
- Starpharma receives $4.0M R&D tax incentive refund
Later from Starpharma
- First Asian Regulatory Approvals Received for VivaGel BV
- Promising efficacy signals observed in ongoing DEP trials
- Positive results with Targeted DEP using antibody fragment
- VivaGel BV regulatory approvals continue in Asia
- DEP irinotecan synergistic with Lynparza in refractory model
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma